These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 36315914)

  • 1. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer.
    Sadik H; Pritchard D; Keeling DM; Policht F; Riccelli P; Stone G; Finkel K; Schreier J; Munksted S
    JCO Precis Oncol; 2022 Oct; 6():e2200246. PubMed ID: 36315914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
    John A; Shah RA; Wong WB; Schneider CE; Alexander M
    Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
    Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
    Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer.
    Hofmarcher T; Malmberg C; Lindgren P
    Front Med (Lausanne); 2023; 10():1119506. PubMed ID: 36891190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.
    Gross CP; Meyer CS; Ogale S; Kent M; Wong WB
    J Natl Compr Canc Netw; 2022 May; 20(5):479-487.e2. PubMed ID: 35545174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.
    Tsimberidou AM; Elkin S; Dumanois R; Pritchard D
    Clin Lung Cancer; 2020 Nov; 21(6):477-481. PubMed ID: 32718774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.
    Castellanos EH; Orlando A; Ma X; Parikh RB; O'Connell G; Meropol NJ; Hamrick J; Adamson BJS
    JCO Oncol Pract; 2020 Oct; 16(10):e1216-e1221. PubMed ID: 32496874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
    Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
    Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
    Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis.
    Kästner A; Kron A; van den Berg N; Moon K; Scheffler M; Schillinger G; Pelusi N; Hartmann N; Rieke DT; Stephan-Falkenau S; Schuler M; Wermke M; Weichert W; Klauschen F; Haller F; Hummel HD; Sebastian M; Gattenlöhner S; Bokemeyer C; Esposito I; Jakobs F; von Kalle C; Büttner R; Wolf J; Hoffmann W
    Lancet Reg Health Eur; 2024 Jan; 36():100788. PubMed ID: 38034041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
    Hardtstock F; Myers D; Li T; Cizova D; Maywald U; Wilke T; Griesinger F
    BMC Cancer; 2020 Mar; 20(1):260. PubMed ID: 32228520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
    Kruglyak KM; Lin E; Ong FS
    Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing personalized pathways for cancer follow-up care in the United States: Proceedings from an American Cancer Society-American Society of Clinical Oncology summit.
    Alfano CM; Mayer DK; Bhatia S; Maher J; Scott JM; Nekhlyudov L; Merrill JK; Henderson TO
    CA Cancer J Clin; 2019 May; 69(3):234-247. PubMed ID: 30849190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine.
    McGowan ML; Settersten RA; Juengst ET; Fishman JR
    Urol Oncol; 2014 Feb; 32(2):187-92. PubMed ID: 24445286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action.
    Baird AM; Westphalen CB; Blum S; Nafria B; Knott T; Sargeant I; Harnik H; Brooke N; Wicki N; Wong-Rieger D
    Health Sci Rep; 2023 Jun; 6(6):e1349. PubMed ID: 37359405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
    Lynch JA; Berse B; Rabb M; Mosquin P; Chew R; West SL; Coomer N; Becker D; Kautter J
    BMC Cancer; 2018 Mar; 18(1):306. PubMed ID: 29554880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe.
    Hofmarcher T; Lindgren P; Wilking N
    J Cancer Policy; 2022 Dec; 34():100362. PubMed ID: 36087918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.
    Rivera MP; Charlot M; Durham DD; Throneburg A; Lane LM; Perera P; Samulski TD; Henderson LM
    Chest; 2021 Sep; 160(3):1121-1130. PubMed ID: 33887243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blueprint for cancer research: Critical gaps and opportunities.
    Elmore LW; Greer SF; Daniels EC; Saxe CC; Melner MH; Krawiec GM; Cance WG; Phelps WC
    CA Cancer J Clin; 2021 Mar; 71(2):107-139. PubMed ID: 33326126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.